CYTK - Cytokinetics may be worth $90+ a share in potential acquisition after Phase 3 data
2023-12-27 10:29:37 ET
More on Cytokinetics
- Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)
- Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten
- Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript
- Cytokinetics gains on positive Phase 3 data for heart disease therapy
- Cytokinetics soars amid report of Novartis, AstraZeneca takeover interest
For further details see:
Cytokinetics may be worth $90+ a share in potential acquisition after Phase 3 data